Literature DB >> 33992976

Chemical profile and potential mechanisms of Huo-Tan-Chu-Shi decoction in the treatment of coronary heart disease by UHPLC-Q/TOF-MS in combination with network pharmacology analysis and experimental verification.

Liangliang He1, Han Jiang2, Taohua Lan3, Yuan Qiu4, Kefeng Yang1, Keji Chen5, Xinsheng Yao6, Zhihong Yao7, Weihui Lu8.   

Abstract

Huo-Tan-Chu-Shi Decoction (HTCSD), a traditional Chinese medicine (TCM) prescription within Guangdong Provincial TCM Hospital (the largest TCM hospital in China), is used for effective clinical treatment of coronary heart disease (CHD) caused by phlegm-dampness syndrome with high incidence in the hot and humid climate of Lingnan region. However, its chemical components responsible for the therapeutic effects remain unclear, which restricts its application and further development. Hence, a detailed workflow, combing with UHPLC-Q/TOF-MS, network pharmacology analysis and experimental verification, was proposed and applied to characterize the chemical profile and potential mechanism of HTCSD against CHD. As a result, a total of 130 components from all six composed herbal medicines were characterized in a rapid and sensitive manner through UHPLC-Q/TOF-MS, of which 33 compounds were unambiguously confirmed with reference standards. Consequently, based on the integrated pharmacology network of "herbs-chemicals-targets-pathways-therapeutic effects", four chemicals (magnoflorine, menisperine, 13-hydroxyberberine, luteolin) with four CHD related targets (SRC, MAPK1, EGFR and AKT1) were considered as the key components and targets of HTCSD in the treatment of CHD. Furthermore, the effect of HTCSD was confirmed in animal experiments by enhancing the phosphorylation of MAPK, and the published literature and molecular binding results suggested that magnoflorine and luteolin tended to be the critical compounds involved in the process. Taken together, the characterization of chemical profile combined with network pharmacology analysis and experimental verification not only provided an efficient insight into the overall chemical profile of HTCSD but also revealed the potential pharmacological components and mechanisms of HTCSD against CHD, which laid a necessary chemical and biological basis for the discovery of in vivo bioactive components and the further revelation of functionary mechanism.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemical profile; Coronary heart disease; Huo-Tan-Chu-Shi decoction; Network pharmacology; Traditional Chinese medicine prescription

Year:  2021        PMID: 33992976     DOI: 10.1016/j.jchromb.2021.122729

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

1.  Efficacy of Wen-Dan Decoction in the treatment of patients with coronary heart disease: A protocol for systematic review and meta-analysis.

Authors:  Xiaoyu Zhang; Yingwei Wang; Lufei Liu; Hui Jiang; Jing Wang; Yang Xiao; Jianwei Wang
Journal:  Medicine (Baltimore)       Date:  2022-01-07       Impact factor: 1.889

2.  Applying Four-Step Characteristic Ion Filtering with HPLC-Q-Exactive MS/MS Spectrometer Approach for Rapid Compound Structures Characterization and Major Representative Components Quantification in Modified Tabusen-2 Decoction.

Authors:  Yu Zhao; Xin Dong; Zhi Wang; Rui Dong; Ren Bu; Qianxi Feng; Peifeng Xue; Bi Qu
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-31       Impact factor: 2.629

3.  Mechanism of Action of Flavonoids of Oxytropis falcata on the Alleviation of Myocardial Ischemia-Reperfusion Injury.

Authors:  Yang Guo; Ben-Yin Zhang; Yan-Feng Peng; Leng Chee Chang; Zhan-Qiang Li; Xin-Xin Zhang; De-Jun Zhang
Journal:  Molecules       Date:  2022-03-05       Impact factor: 4.411

4.  Nontargeted Metabolomic Profiling of Huo-Tan-Chu-Shi Decoction in the Treatment of Coronary Heart Disease with Phlegm-damp Syndrome.

Authors:  Zhaoying Liang; Qiaohuang Zeng; Xiaomin Ou; Jing Cai; Taohua Lan; Weihui Lu
Journal:  Cardiol Res Pract       Date:  2022-08-12       Impact factor: 1.990

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.